Who are Human Papillomavirus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Flu Vaccine, HPV vaccine, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix TM, HPV-16/18 vaccine, GSK580299 (Cervarix).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/human-papillomavirus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Human Papillomavirus — Competitive Intelligence Brief

Human Papillomavirus (Human Papillomavirus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prophylactic vaccine. Area: Oncology / Immunology / Infectious Disease.

marketed Prophylactic vaccine Human Papillomavirus capsid protein (L1) Oncology / Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Human Papillomavirus (Human Papillomavirus) — Peking Union Medical College Hospital. Human Papillomavirus (HPV) vaccines stimulate the immune system to produce antibodies against specific HPV types, preventing infection and associated cancers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Human Papillomavirus TARGET	Human Papillomavirus	Peking Union Medical College Hospital	marketed	Prophylactic vaccine	Human Papillomavirus capsid protein (L1)
Flu Vaccine	Flu Vaccine	La Fundacion Favaloro para la Investigacion y la Docencia Medica	marketed	Prophylactic vaccine	Influenza A and B viral hemagglutinin and neuraminidase surface antigens
HPV vaccine	HPV vaccine	Fondazione IRCCS Policlinico San Matteo di Pavia	marketed	Prophylactic vaccine	Human papillomavirus (HPV) capsid proteins / L1 antigen
Recombinant Human Papillomavirus Bivalent Vaccine	Recombinant Human Papillomavirus Bivalent Vaccine	National Cancer Institute (NCI)	marketed	Prophylactic vaccine	Human papillomavirus types 16 and 18 (HPV-16, HPV-18)
Cervarix TM	Cervarix TM	GlaxoSmithKline	phase 3	Prophylactic vaccine	HPV types 16 and 18 (L1 capsid protein)
HPV-16/18 vaccine	HPV-16/18 vaccine	Shanghai Zerun Biotechnology Co.,Ltd	phase 3	Prophylactic vaccine	HPV-16 and HPV-18 L1 capsid proteins
GSK580299 (Cervarix)	GSK580299 (Cervarix)	GlaxoSmithKline	phase 3	Prophylactic vaccine	HPV type 16 and 18 L1 capsid protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prophylactic vaccine class)

GlaxoSmithKline · 5 drugs in this class
La Fundacion Favaloro para la Investigacion y la Docencia Medica · 1 drug in this class
Fondazione IRCCS Policlinico San Matteo di Pavia · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Shanghai Zerun Biotechnology Co.,Ltd · 1 drug in this class
Murdoch Childrens Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Human Papillomavirus — Competitive Intelligence Brief. https://druglandscape.com/ci/human-papillomavirus. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab